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This supplement summarizes the proceedings of an Astellas-
sponsored integrated symposium entitled ‘Breaking the cycle
of recurrent Clostridium difﬁcile infections’, which took place
during the 22nd European Congress for Clinical Microbiology
and Infectious Diseases (ECCMID) held in London, UK, from
31 March to 3 April 2012. The symposium drew a large audi-
ence, reﬂecting the importance of C. difﬁcile as the leading
cause of infectious nosocomial diarrhoea in developed coun-
tries and the rapidly growing interest in this pathogen. C. dif-
ﬁcile rose to prominence in the late 1970s following the
widespread use of broad-spectrum antibiotics, but was gen-
erally regarded as a mildly troublesome side effect of antibi-
otic use, because most patients experienced few
complications at that time. The dramatic rise in the incidence
of C. difﬁcile infection (CDI) that has occurred since 2000,
together with increased CDI-related morbidity and mortality,
has changed our perceptions of this Gram-positive, spore-
forming, anaerobic bacterium.
Gaining an accurate picture of the incidence of CDI and
the number of new cases that arise each year is fundamental
to understanding the spread of C. difﬁcile within healthcare
facilities, within the community, and from other reservoirs of
infection. In the ﬁrst article of this supplement, Professor
Emilio Bouza explores current epidemiological knowledge of
CDI in Europe, and emphasizes how this is undermined by
low levels of awareness of CDI in many countries and
marked variations in testing frequency and reporting [1]. This
problem is highlighted by results from a multicentre point-
prevalence study of CDI in Spain, which showed that two-
thirds of CDI episodes had been either misdiagnosed or
undiagnosed because of low clinical suspicion of CDI or the
use of diagnostic tests with low sensitivity [2]. This is impor-
tant because of the signiﬁcant clinical and economic burden
of CDI, which, as Professor Bouza emphasizes, is exacer-
bated by high rates of CDI recurrence. Recently, in the UK,
the National Institute for Health and Clinical Excellence esti-
mated the impact of reducing a subset of healthcare-associ-
ated infections, namely methicillin-resistant Staphylococcus
aureus bloodstream infections and CDI. A 5% reduction in
C. difﬁcile cases would reduce National Health Service costs
by an estimated £4.7 million annually, and a 15% decrease
would reduce costs by £13.9 million (http://www.nice.org.uk/
nicemedia/live/13763/59579/59579.pdf). Most of the incre-
mental costs associated with CDI arise from extended hospi-
talization, with CDI patients spending 1–3 weeks longer in
hospital than non-infected matched controls [3,4]. Recurrent
CDI leads to re-hospitalization and additional costs of treat-
ment and isolation. The burden of CDI often exceeds that of
other infectious diseases, amounting to €3000 million per
year in Europe alone, and is projected to rise commensu-
rately with a growing elderly population [4].
The dramatic rise in the incidence of CDI has placed
greater demands on laboratory diagnostic services but, as
Professor Mark Wilcox discusses in the second article, in
many countries the diagnosis of CDI remains suboptimal [5].
The absence of a single reference standard and the existence
of two reference methods, one that detects C. difﬁcile toxin
(cytotoxin assay) and another that detects the presence of
toxigenic strains (cytotoxigenic culture), have resulted in
confusion. In recent diagnostic guidelines described by Pro-
fessor Wilcox, the European Society of Clinical Microbiology
and Infectious Diseases (ESCMID) recommends a two-step
approach to diagnosis, using tests that combine sensitivity,
speciﬁcity, and rapidity [6]. However, laboratories rarely
adhere to such guidelines, with most using a single enzyme
immunoassay for toxin detection [7,8]. Given that these tests
may miss up to 20% of positive cases and falsely identify up
to two of every ten cases as positive, incorrect results may
be obtained with a worryingly high frequency [9]. The
Department of Health in the UK has addressed this problem
by commissioning a large-scale observational study of diag-
nostic testing procedures and the subsequent development
of an optimized diagnostic algorithm. As lead investigator,
Professor Wilcox presents preliminary results from this
study, and highlights the importance of potential C. difﬁcile
faecal excretors–patients colonized with C. difﬁcile but with
no demonstrable toxin in their faeces.
With up to 25% of CDI patients experiencing disease
recurrence within 30 days of treatment with standard antibi-
otic therapy, recurrent CDI is a major complication of treat-
ment [10–12]. Identifying the patients who are most at risk
of developing recurrent CDI following successful treatment
of a primary episode provided the focus for Professor Ciara´n
Kelly’s presentation, and is the topic of the third article in
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this supplement [13]. Patients known to be at risk of CDI
recurrence include those aged 65 years or over [14],
patients with severe comorbidities as indicated by high
scores on the Charlson comorbidity index [14], patients with
renal impairment [15], patients who are immunocompro-
mised [16], and patients with continued exposure to antibac-
terial agents [14]. Patients who fail to mount a systemic
anti-toxin A response on day 12 after a ﬁrst CDI episode
are also considered to be at higher risk of CDI recurrence
[15]. Studies of risk factors for recurrent CDI have enabled
the development of a number of clinical prediction tools
that, as Professor Kelly demonstrates, can be applied by clini-
cians to identify patients at highest risk of recurrent CDI.
This potentially allows for more targeted preventive and
therapeutic interventions for patients with CDI.
Against a background of rising CDI incidence and disease
of greater severity, Professor Oliver Cornely addresses the
need for new treatments for CDI – and considers brieﬂy the
development pipeline – in the ﬁnal article of this supplement
[17]. Although several investigational approaches are under
evaluation for CDI, including speciﬁc monoclonal anti-toxin
antibodies to C. difﬁcile [12] and faecal microbiota transplan-
tation [18], antibiotic therapy continues to underpin treat-
ment [19,20]. Oral metronidazole and vancomycin are the
current standard therapies [19,20]. Some hospitals in Europe
also include rifaximin in treatment regimens [21], as studies
have suggested that it may be beneﬁcial for multiple recur-
rent and unresponsive CDI [22]. Approval of the ﬁrst-in-
class macrocycle ﬁdaxomicin by the European Medicines
Agency for treatment of CDI in adult patients has expanded
the treatment options [23]. Professor Cornely presents data
from the two phase 3 registration trials of ﬁdaxomicin vs.
vancomycin in patients with mild, moderate and severe CDI
(but excluding fulminant CDI) as deﬁned by ESCMID criteria
[10,19,24]. These trials show that ﬁdaxomicin achieves simi-
lar rates of clinical cure as oral vancomycin, but with signiﬁ-
cantly lower rates of disease recurrence [10,24]. This
translates into superior rates of sustained clinical cure,
deﬁned as clinical cure plus no recurrence within 30 days
[10,24]. Fidaxomicin has similar activity to vancomycin
against the hypervirulent 027 ribotype, although rates of clin-
ical cure are lower and rates of recurrence are higher with
both antibiotics than in patients with other C. difﬁcile strains
[25].
Cost is an important issue with any new medication, and
is one that applies to ﬁdaxomicin. In assessing cost, it is
important to consider the potential impact of the therapy on
reducing disease burden, in addition to drug acquisition
costs. As patients with CDI spend up to a week or longer in
hospital than non-infected patients, increased duration of
hospitalization is a major contributor to the excess costs
associated with CDI [3,26]. The need for rigorous hygiene,
environmental decontamination, cohort isolation and ward
closures adds to these costs [26]. Reducing the rate of CDI
recurrence would be expected to reduce the costs associ-
ated with repeated courses of treatment, and help to reduce
the rate of person-to-person transmission [10].
By increasing clinical suspicion of CDI in patients present-
ing with unexplained diarrhoea, adopting validated diagnostic
algorithms for CDI detection, and using new treatment
options that offer sustained clinical cure, we may be able to
break the cycle of CDI and greatly reduce the risk of recur-
rence. We hope that this supplement will be of interest and
beneﬁt to clinicians, microbiologists and other healthcare
professionals working to optimize patient management and
prevent the spread of C. difﬁcile in both the hospital environ-
ment and the wider community.
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